Strategic Objective
The TGC method of tgcBIOMICS is based on the use of bacterial gene carriers for targeted genetic conditioning. The platform technology is used in the market of recombinant proteins, DNA vaccination and gene therapy.
| |
Use of this technology in these three areas offers customers of tgcBIOMICS access to content that gives them an outstanding position among the growing competition. tgcBIOMICS supplies the technology and expertise (Fig. 1). The technology will be marketed through outlicensing and production on customer demand. In the early phase, the enterprise's customers are researching firms and institutes, later increasingly medium-sized biotech/medical industrial enterprises and finally internationally established large corporations acting in the sector of recombinant proteins for engineering and medicine.
|  |
|
tgcBIOMICS aims at a leading position on the international market in the use of bacteria to transfer nucleic acids to control biological processes (BIOMICS).
Fig.1: product portfolio
The successful TGC method has the potential to take up a unique key position in the development of BIOMICS. The extraordinary advantages for users and customers form the basis for the upcoming economic success of tgcBIOMICS
Until the platform technology is ready for the market, tgcBIOMICS achieves turnover by marketing services in "recombinant DNA technology", exhausting existing official approvals. Synergies arise in vaccine development.
|
|
TGC Biomics GmbH, Carl-Zeiss-Str. 51, 55129 Mainz | Tel.+49(0)6131 62757-10 | mail@tgcbiomics.de
